Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and ...

As the number of RSV infections rises, two recent studies found that protecting babies against the disease prevented ...

In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal ...

How effective is nirsevimab at preventing respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD), ...

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

Infants who receive nirsevimab may have a lower risk for hospitalisation for RSV-related lower respiratory tract infection ...

Scientists have uncovered strong evidence that infection with RSV in the first months of life can significantly raise the ...

The Public Health Department's improved dashboard includes data on real-time spread and vaccination rates for the three ...

Credit: Getty Images. RSV primarily affects children and older adults, and can lead to severe illness or death. Respiratory syncytial virus (RSV) affects infants, young children, and older adults, ...

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...

RSV causes more severe respiratory infection than influenza in patients with malignancy, increasing risks for ICU admission and mortality.

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most ...